Structural Formula (Image 01)
Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate Kit
Product Images NDC 0378-7303
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate (NDC 0378-7303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Concentrations (Image 02)
Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)
This document may represent data obtained from a clinical trial evaluating the efficacy of a combination of Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate tablets compared to a placebo group. The results showed a mean percent reduction in lesion counts in the intent-to-treat population. However, the document is incomplete and difficult to interpret without additional context.*
Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)
Blister (Image 05)
This appears to be a section from instructions for birth control pills. It explains how to properly start taking the pills based on the day of the week a person's period starts. It includes a chart with labels for each day of the week, and instructions to "TAKE PILLS IN THIS DIRECTION FROM LEFT TO RIGHT." The product is for prescription only with the code "NG 0376730385 Rx only".*
Blister (Image 06)
This is a set of instructions for starting contraceptive pills on day-1 of the menstrual cycle. A label sticker with day labels starting from the first day of the user's period is provided. It also includes a direction to take the pills from left to right. There is a code number, NG 0376730385, followed by a warning that the pills are available by prescription only. The text includes abbreviated names of the days of the week in English.*
3s Carton (Image 07)
This appears to be the description of a birth control drug called Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets. The text suggests that these pills should be taken daily as prescribed to prevent pregnancy. They contain Ferrous Fumarate, which is not for use during pregnancy. The dosage and prescribing information can be found in the enclosed package insert. The tablets should be stored at room temperature and protected from light. However, some of the text is unreadable, making it difficult to understand the complete details.*
Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)
This appears to be a list of studies related to women's contraceptive use and their health. The studies include The NICHD Women's Contraceptive Study (2002), Franch E3N cohort Sty (2005), Shanga Women's Health Sy, The Nurse's Health Study I (2010), Danish Sax Hormone Register Study (2017), among others. The data includes information about ever and current use of contraceptives.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
